{"id":"W4399765099","doi":"10.1200/jco.23.01680","title":"Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in <i>PIK3CA</i>-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Inflammatory mediators and NSAID effects","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôtel-Dieu de Québec","funders":"National Cancer Institute; National Institutes of Health; Ipsen; Parker Institute for Cancer Immunotherapy; Astellas Pharma; Eisai; Genentech; AstraZeneca; Celgene; FibroGen; Alliance for Clinical Trials in Oncology Foundation; Chugai Pharmaceutical; Agios Pharmaceuticals","keywords":"Medicine; Internal medicine; Hazard ratio; Oncology; Colorectal cancer; Clinical endpoint; Cancer; Celecoxib; Proportional hazards model; Randomized controlled trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004004319,0.0002585332,0.001897654,0.0001966892,0.00004237126,0.00002104547,0.00009386943,0.000568876,0.0002356606],"category_scores_gemma":[0.001010842,0.0001707397,0.0003407333,0.000416246,0.0002278064,0.000240733,0.00003947028,0.002121793,0.0000168197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005499643,"about_ca_system_score_gemma":0.003851481,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002996606,"about_ca_topic_score_gemma":0.001416088,"domain_scores_codex":[0.9959282,0.0005679145,0.002239537,0.0003441758,0.0004815091,0.0004386839],"domain_scores_gemma":[0.9963082,0.001605036,0.0009845035,0.0001954251,0.0003611849,0.000545651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1135696,0.006272517,0.0848438,0.002328943,0.002425177,0.1109533,0.001646284,0.0005953411,0.2894919,0.0004907501,0.0169149,0.3704675],"study_design_scores_gemma":[0.1117344,0.0908834,0.2899973,0.009100835,0.002255595,0.002283747,0.001438221,0.01099912,0.08672102,0.0002427167,0.39271,0.00163359],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897512,0.001619306,0.0001494294,0.003497913,0.003760276,0.0005092966,0.00001625294,0.00004050852,0.000655848],"genre_scores_gemma":[0.9937491,0.002025005,0.0003411118,0.001131537,0.00224357,0.00002661394,0.000009889008,0.00004667106,0.0004265215],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3757951,"threshold_uncertainty_score":0.9218252,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05588666838383798,"score_gpt":0.4207957034389528,"score_spread":0.3649090350551148,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}